1 research outputs found
Phase II trial of a nonâplatinum triplet for patients with advanced nonâsmall cell lung carcinoma (NSCLC) overexpressing ERCC1 messenger RNA
Background We prospectively evaluated the efficacy and toxicity of a nonâplatinum triplet regimen for patients with advanced nonâsmall cell lung cancer (NSCLC) expected to be platinumâresistant. Methods Patients were diagnosed with NSCLC using endobronchial ultrasonography with a guide sheath as a core biopsy. RNA was immediately isolated from unfixed biopsy specimens, and quantitative realâtime reverse transcriptionâPCR assays were performed to determine ERCC1 messenger RNA expression. Patients with advanced, untreated NSCLC showing high ERCC1 levels (ÎCt ⧠6.5) were assigned a nonâplatinum triplet regimen of irinotecan and paclitaxel plus bevacizumab. The primary end point was the objective response rate (ORR). Results A total of 141 untreated patients were evaluated and 30 patients were entered into this phase II trial. The ORR was 66.7% (95% confidence interval [CI] 47.2â82.7) and median progressionâfree survival (PFS) was 215 days. Grade 4 thrombosis occurred in one patient, but other toxicities were mild and controllable. Fiftyâsix patients were treated with platinumâcontaining regimens and 24 patients responded (ORR 42.8%, 95% CI 29.7â56.7). Twentyânine of these patients had high ERCC1 levels, of which 6 patients responded; 27 patients had low ERCC1 levels, 18 patients responded (P = 0.0053 by Fisherâs exact test). Conclusion The triplet combination might be effective for patients with advanced, untreated NSCLC overexpressing ERCC1. ERCC1 messenger RNA levels may be a predictive factor for response to platinumâcontaining regimens